Purpose: This study aims to investigate whether the plasma level of glutathione S-transferase P1-1 (GSTP1-1), which is a phase II detoxifying enzyme known to be a resistance factor for anticancer drugs, could be a prognostic factor of de novo non-Hodgkin lymphoma (NHL) in clinical stages (CSs) III and IV.
INTRODUCTION
Although therapy for advanced non-Hodgkin's lymphoma (NHL) has greatly improved over the last two decades, prognosis for approximately half of the patients remains poor. Factors defining prognosis in NHL are those related to tumor burden [clinical stage (CS), lactate dehydrogenase (LDH), extranodal involvement, etc.], status of patients (performance status, age, etc.), and tumor cell properties [histologic aggressiveness, expression of genes relevant to cell survival (p53, bcl-2), drugresistant factors, etc; refs. [1] [2] [3] [4] [5] . As chemotherapy is inevitable for treatment of NHL at advanced stages such as III and IV, drug resistance factors may be one of the most viable prognosis defining factors. However, the implication of drug resistance factors for prognosis of NHL has not been carefully elucidated.
Drug resistance is generally mediated by metabolic pathways, including phase I and phase II enzymes and the phase III efflux pump system. Phase I enzymes such as cytochrome p450s exert their function through oxidation, reduction, and hydrolysis of xenobiotics. Of the cytochrome p450 isozymes, CYP1B1 is known to be expressed in tumor cells (6) , but it is reported to inactivate only one anticancer drug, docetaxel, nonrelevant to NHL treatment (7) . The phase III efflux pump, such as Pglycoprotein (multidrug-resistant factor), multidrug resistancerelated protein and glutathione S-conjugate pump (GS-X), which actively pump out xenobiotics from the cells, have been shown to be involved in the inactivation of a wide variety of anticancer drugs, including adriamycin, vincristine, and VP-16 (8 -10) . However, multidrug-resistant factor is reportedly irrelevant to the prognosis of NHL (11, 12) , possibly because it is mainly implicated in acquired drug resistance (13, 14) . Multidrug resistance-related protein is also reportedly proven not to be correlative to the prognosis of NHL (15) . Phase II enzymes such as aldehyde dehydrogenase-3, UDP-glucuronyltransferase, and glutathione S-transferase, which conjugate xenobiotics to inactivate them, are also known to be resistant factors to certain anticancer drugs. Aldehyde dehydrogenase-3 catalyzes the detoxification of cyclophosphamide, oxazaphosphorine, ifosfamide, etc. (16), and UDP-glucuronyltransferase conjugates mitoxantrone but not adriamycin or vincristine, which are routinely used for treating NHL (17) . Glutathione S-transferase, on the other hand, has been shown to function as a multidrugresistant factor for melphalan and chlorambucil by glutathione conjugation, and for adriamycin, cyclophosphamide and CDDP by a conjugation-unrelated mechanism (18 -24) . This enzyme is often increased in malignant tissues, irrespective of prior chemotherapy, and is suggested to serve as a multidrug-resistant factor in both inherent and acquired fashions (19, 25, 26) . In fact, there are recent reports that disclosed a correlation between glutathione S-transferase P1-1 (GSTP1-1) expression in tumor tissues and the prognosis in ovarian cancer as well as in head and neck cancer (27, 28) .
There have been a few reports about GSP1-1 expression with special reference to their chemotherapy responsiveness in NHL. Berhame et al. (29) , applying immunohistochemistry, found no significant correlation between chemosensitivity and GSTP1-1 expression, but they dealt with only nine cases. Rodrigeuz et al. (30) obtained similar results using dot blot analysis, but 16 of the 41 cases they studied had anamnesis of prior chemotherapy and therefore are not suitable for analysis of prognostic factors. Ribrag et al. (31) studied GSTP1-1 expression by immunohistochemistry in 69 diffuse large B-cell lymphoma patients and found a significant correlation between the staining intensity and complete remission rate but not between the intensity and overall survival. They included 41 cases at stages I and II, which may not be suitable for studying prognostic factors because curability and prognosis of patients at these early stages may not merely reflect sensitivity of tumor cells to chemotherapy.
We have previously established an ELISA for plasma GSTP1-1 (32, 33) . In the present study, therefore, we investigated whether or not the plasma GSTP1-1, which reflects the sum of GSTP1-1 expression in total multiple lesions, could be a predictor of the response to cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) treatment and/or the prognosis of untreated NHL (stage III or IV).
MATERIALS AND METHODS
Subjects. This study was approved by the ethics committee of Sapporo Medical University. Eighty patients who were histopathologically diagnosed as having NHL at the 4th Department of Internal Medicine of Sapporo Medical University Hospital and affiliated hospitals during the period of January 1994 to March 1999 were enrolled after strict informed consent was provided by each patient. The study group consisted of 43 males and 37 females, with a mean age of 60 years . All lymphoma tissues were histologically evaluated by two independent reviewers (M. S. and T. I.) in the Department of Clinical Pathology of Sapporo Medical University. Forty-two patients were diagnosed as having diffuse large B-cell lymphoma, 30 with low-grade B-cell lymphoma, 3 with marginal-zone B-cell lymphoma, and 2 with lymphoblastic lymphoma in accordance with the World Health Organization classification (34) . Lymphomas were also classified as indolent type (30 low-grade B-cell lymphomas and 3 marginal-zone B-cell lymphomas), aggressive type (42 diffuse large B-cell lymphomas) or very aggressive type (2 lymphoblastic lymphomas) according to the criteria of the International Lymphoma Study Group (35) . The distribution of clinical stages was 12 patients in CS I, 14 in CS II, 25 in CS III, and 29 in CS IV.
Blood samples were kindly provided by forty healthy volunteers with strict informed consent.
Chemotherapy Protocol. All of the patients at CS III or CS IV were treated with CHOP (750 mg of cyclophosphamide per square meter of body-surface area, 50 mg adriamycin per square meter, and 1.4 mg of vincristine per square meter (up to a maximal dose of 2 mg) on day 1 as well as 40 mg of prednisolone per square meter per day for 5 days; ref. 36 ) and were treated every 3 weeks for 8 cycles. Treatment was stopped if lymphoma progressed, if the patients declined to continue or at the discretion of the investigator in cases of either intercurrent illness, or where adverse effects were displayed.
Tumor responses were assessed after 8 cycles of chemotherapy or at the end of treatment and were judged as complete response, unconfirmed complete response, partial response, stable disease, or progressive disease according to the response criteria of the International Workshop (37).
Plasma GSTP1-1 Measurement by ELISA. Before treatment, blood samples were gently drawn from the cubital vein of the patients by syringes that had been wetted with EDTA-2Na and transferred to plastic tubes containing EDTA2Na. They were then immediately centrifuged at 1,200 ϫ g at 4°C for 15 minutes. Plasma samples were separated with a Pasteur pipette, taking care to avoid collecting platelets or blood cells, and filtered through . The cutoff value was set at 22.6 ng/mL (mean ϩ 2SD). There was a significant stepwise increment from CS I to CS IV (Kruskal-Wallis test, P Ͻ 0.05). There was no significant difference among the histologic types. millipore membrane (0.45 m) to avoid contamination of blasts. Samples were stored at Ϫ20°C, and after thawing to room temperature, we subjected them to a sandwich ELISA using monoclonal and polyclonal antibodies established in our laboratory (32, 33) .
Immunohistochemical Analysis of GSTP1-1. Lymph node tissues biopsied from patients before treatment were fixed in formalin and embedded in paraffin. Then we cut the tissues into sections 3-m thick and stained for GSTP1-1 using the mouse monoclonal antibody 5F (32) or for controls using normal mouse IgG (DAKO, Glostrup, Denmark) for the first antibodies and biotinylated horse antimouse immunoglobulin G (Vector Laboratories, Burlingame, CA) for the second. GSTP1-1 protein was visualized with a Vectastain ABC kit (Vector Laboratories) using 3-3Ј-diaminobenzidine (Sigma Chemical Co. St. Louis, MO) as a chromogen. Hematoxylin was not used because it would have disturbed the assessment of immunostaining intensity by the imaging analyzer. We also did the immunostaining for CD20 in the serial sections to examine the percentage of lymphoblasts. We carried our image analysis of staining for GSTP1-1 by using an AxioCam photomicroscope and the KS-400 image analyzing system (Carl Zeiss Vision GmbH, Hallbermoss, Germany) in accordance with the method of Kato et al. (38) with minor modifications. In brief, five randomly selected microscopic images 50 ϫ 50 m 2 each, in which the percentages of lymphoblasts were more than 90%, were selected. They were imported into the KS400; brownstained areas, which represented positively stained GSTP1-1 in each lymphoma cell, were converted into a 255-grade gray scale. The sum of gray scale intensities in each 50 ϫ 50 m 2 square was calculated by using the KS-400 image analyzing program, and the relative intensity was represented by the ratio of the intensity to that of the serial section immunostained by normal mouse IgG. The mean of the five relative intensities in each section was calculated.
Statistical Analysis. Correlations between the plasma GSTP1-1 concentration and the clinical stage or the histologic classification were assessed by the Kruskal-Wallis test. The correlation between plasma GSTP1-1 concentration and intensity of GSTP1-1 expression was assessed by the Pearson's test. The correlation between the CR rates and relative intensity of GSTP1-1 expression was assessed by the 2 test. The correlations between the CR rates and plasma GSTP1-1 concentration or factors from the International Prognostic Index (1) were assessed by Fisher's exact probability test. Correlations between the plasma GSTP1-1 concentration and progression-free or overall survival curves were constructed with the Kaplan-Meier method. Multivariate analysis was done with the COX proportional hazards model.
RESULTS

Plasma GSTP1-1 Concentration in NHL.
The mean plasma GSTP1-1 concentration in 40 healthy subjects was 13.8 Ϯ 4.4 ng/mL. The cutoff value was set at 22.6 ng/mL, which was the mean ϩ 2SD (Fig. 1A) . There was a significant stepwise increment of plasma GSTP1-1 concentration from CS I to CS IV (Kruskal-Wallis test, P Ͻ 0.05), although no significant difference was observed between those of CS III and CS IV. Of the 54 patients with CS III or IV, 28 (52%) had elevated plasma GSTP1-1 levels. There was no statistical difference between any indolent, aggressive, or very aggressive lymphoma (P ϭ 0.64, Fig. 1B ). Because CS I or CS II NHL is not usually treated with chemotherapy and therefore not relevant for GSTP1-1 study, further investigation was done only on CS III and CS IV NHL.
Immunohistochemistry of GSTP1-1 and Its Quantitative Analysis. The expression of GSTP1-1 in lymphoma tissue was investigated by immunohistochemical staining in 26 patients with CS III and CS IV. In Fig. 2 , three representative cases (case 1, A-C; case 2, D-F; case 3, G-I) with different staining intensities are shown, although all of the histologic types were the same; diffuse large B-cell lymphoma was revealed in A, D, and G. In Fig. 2B , the lymphoma cells were strongly stained for GSTP1-1 throughout the lesion. The figure with higher magnification revealed that GSTP1-1 is located mainly in cytoplasm and, although weakly, in nuclei (Fig. 2C) . Figure 2E shows lymphoma tissue in which lymphoma cells were weakly stained for GSTP1-1 throughout the lesions. In contrast, the lymphoma cells in Fig. 2H were almost negative for GSTP1-1. Figures 2C, F , and I show higher magnification (50 ϫ 50 m 2 ) of 2B, 2E, and 2H, respectively. With five of such higher magnifications, randomly selected, the mean GSTP1-1 intensity of lymphoma cells was calculated as described in "Materials and Methods." Plasma GSTP1-1 Concentrations and Immunohistochemical GSTP1-1 Expression Levels in Biopsied Lymphoma Tissue. The relationship between plasma GSTP1-1 concentrations and tissue expression levels of GSTP1-1 was studied (Fig. 3) . Although the plasma GSTP1-1 concentrations tended to correlate with relative intensities of immunohisto- Fig. 3 Relationship between plasma GSTP1-1 concentration and immunohistochemical GSTP1-1 expression level in biopsied lymphoma tissues. The plasma GSTP1-1 concentration tended to correlate with relative intensity of immunohistochemical staining; the correlation was not statistically significant (r ϭ 0.45, P ϭ 0.07).
Fig. 4
Kaplan-Meier analysis of overall survival in high and low intensity groups of GSTP1-1 expression in NHL. Relative intensity of immunohistochemical staining in biopsied lymphoma tissue of each case was calculated as described in "Materials and Methods." There was no significant difference in overall survival between high and low intensity groups (P ϭ 0.31). * There was no significant difference of complete response rates between the low and high intensity groups. chemical findings in biopsied lymphoma tissue, the correlation was not statistically significant (r ϭ 0.45, P ϭ 0.07).
Immunohistochemical GSTP1-1 Expression and the Prognosis of NHL. We first investigated the relationship between the relative intensity of GSTP1-1 tissue expression and the prognosis of NHL. We defined the high intensity group as those with relative intensity higher than the median value (10.7) and the low intensity group as those with relative intensity Ͻ10.7. The average CR rates were 46.2% (6 of 13) among patients in the low intensity group and 38.5% (5 of 13) among those in the high intensity group, there being no statistically significant difference between them (P ϭ 0.72, Table 1 ). The median survival time was 44 months for the low intensity group (range, 12-94 months) and 37 months for the high intensity group (range, 6 -96 months), the difference being not significant (P ϭ 0.31, Fig. 4) .
Plasma GSTP1-1 Concentration and the Prognosis of NHL. We next investigated the relationship between the plasma GSTP1-1 level and the responsiveness to chemotherapy. The average CR rates were 55.2% (14 of 26) among patients with low GSTP1-1 and 16.0% (5 of 28) among those with high GSTP1-1, the difference being statistically significant (P ϭ 0.01; Table 2 ). The median overall survival time was 64 months (range, 9 -102 months) and 25 months (range, 6 -93 months) among patients with low and high plasma GSTP1-1 concentration, respectively (P Ͻ 0.01, Fig. 5 ). Figure 6 shows the influence of plasma GSTP1-1 concentration on the time to progression, with a median time of 58 months (range, 0 -100 months) in patients with low GSTP1-1 levels compared with 12 months (range, 0 -90 months) in those with high GSTP1-1 levels (P Ͻ 0.01).
Plasma GSTP1-1 Concentrations and Prognostic Factors. The components of the international prognostic index for NHL include age, serum LDH, performance status, clinical stage, and extranodal involvement. In this study, the GSTP1-1 levels were compared with NHL prognostic indicators, excluding clinical stage. Univariate analysis showed no significant correlation between plasma GSTP1-1 concentration and any of the NHL prognostic indicators, demonstrating an independency of GSTP1-1 from the known prognostic indicators (Table 3) .
Multivariate analysis also showed a significant correlation between the plasma GSTP1-1 concentration and the overall survival or progression free survival (Table 4) .
DISCUSSION
In the present study, we successfully showed that plasma GSTP1-1 is a useful prognostic factor for NHL at stages III and IV. Specifically, we showed that overall and disease-free survival rates as well as complete response rates of patients with plasma GSTP1-1 above normal levels were lower than those within normal levels. These findings are compatible with the fact that GSTP1-1 is a resistant factor against two major drugs, cyclophosphamide and adriamycin (21) (22) (23) (24) , used in the standard regimen (CHOP) for NHL.
GSTP1-1 is known to conjugate melphalan and chlorambucil with glutathione and export them through the GSX pump. GSTP1-1 has also been shown to endow resistance to 4-HC, the active form of cyclophosphamide, and adriamycin through a conjugation-unrelated mechanism (18, 19, 39) . Although the mechanism of the conjugation-unrelated resistance has not yet been elucidated in detail, it has been proposed recently that GSTP1-1 endows resistance to apoptosis through inhibition of Fig. 5 Kaplan-Meier analysis of overall survival in high and low plasma GSTP1-1 groups of NHL. There was a significant difference in overall survival between the two groups (P Ͻ 0.01).
Fig. 6
Kaplan-Meier analysis of progression-free survival in high and low plasma GSTP1-1 groups of NHL. There was a significant difference in progression-free survival between the two groups (P Ͻ 0.01). (18) . It is also another plausible mechanism that GSTP1-1 sequestrates these drugs in cytosol by direct binding (40) .
Furthermore, we evidenced an independency of plasma GSTP1-1 from other previously accepted prognostic factors, which include age, serum LDH, performance status, clinical stage, and extranodal involvement; this may be reasonably accepted because none of these factors are related to drug resistance whereasGSTP1-1 is.
An obvious advantage of using GSTP1-1 in circulation rather than in tissue as a prognostic marker is, needless to say, the objectiveness in quantitative analysis. Even more importantly, GSTP1-1 expression in a biopsied lymphoma tissue does not necessarily represent that in multiple lesions because malignant tissues are generally heterogeneous (41, 42) , whereas plasma GSTP1-1 level is believed to reflect the sum of GSTP1-1 expression in each lymphoma tissue. Should an advanced patient whose biopsy specimen is negative for GSTP1-1 undergo CHOP therapy, the prognosis may be poor because other lymphoma tissues express high levels of GSTP1-1 and are resistant to CHOP. In fact, in the present study, expression of GSTP1-1 in lymphoma tissue, which did not correlate with plasma GSTP1-1 levels, was not a good indicator of chemotherapy responsiveness or prognosis, in agreement with previous reports (29 -31) .
The postulation that plasma GSTP1-1 reflects the sum of GSTP1-1 expression may be supported by the fact that GSTP1-1 concentrations in culture media of various tumor cell lines well correlate with those of their respective cell lysates (data not shown). With regard to the mechanism of GSTP1-1 being released from cells, it may not be simple leakage because GSTP1-1 in the medium exists in monomer form unlike the intracellular form, which is a homodimer (43) .
Analyses of the gene expression profile of diffuse large B-cell lymphoma by using DNA microarray have been reported recently by three independent groups (44 -46) . Arizadeh et al. (44) and Rosenwald et al. (45) used a common customized cDNA microarray "lymphochip" that did not include the cDNA of the GSTP1-1 gene. Shipp et al. (46) used a customized oligonucleotide microarray "HU6800," which could detect GSTP1-1 gene expression, although their gene expression profile, which determined the prognosis of NHL, did not include that of the GSTP1-1 gene. However, the stage distribution of their cases was uncertain. More importantly, their investigation was carried out with a biopsied specimen, which does not necessarily represent scattered multiple lesions of NHL at advanced stages. It has been also suggested that the microarray analysis they used was less sensitive than conventional methods such as real-time PCR and Northern blotting. For example, Rajeevan et al. (47) reported that differences Ͻ4-fold detected by the microarray method were not always reproducible by real-time PCR.
Incidentally, a report by Schisselbauer et al. (48) indicated that glutathione S-transferase in blasts of chronic lymphatic leukemia was relevant to chlorambucil resistance. This apparently contradicts our present claim that the concentration of glutathione S-transferase in tumor cells may not represent that of total tumor mass in the body because of tumor heterogeneity. However, in chronic lymphatic leukemia, needless to say, blasts are circulating and, unlike lymphoma, heterogeneous sampling could be avoided. Therefore, their results were compatible with ours analyzed by plasma GSTP1-1 measurement in NHL.
Nonetheless, the plasma GSTP1-1 concentration is thus considered to be a useful prognostic factor for NHL at advanced stages. 
